Published in Exp Cell Res on February 12, 2010
Oxygen sensing and hypoxia signalling pathways in animals: the implications of physiology for cancer. J Physiol (2013) 1.35
The role of HIF prolyl hydroxylases in tumour growth. J Cell Mol Med (2010) 1.06
Prolyl hydroxylase PHD3 enhances the hypoxic survival and G1 to S transition of carcinoma cells. PLoS One (2011) 0.94
Expression and DNA methylation levels of prolyl hydroxylases PHD1, PHD2, PHD3 and asparaginyl hydroxylase FIH in colorectal cancer. BMC Cancer (2013) 0.83
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer. Mol Cancer Ther (2004) 2.47
Cleavable ErbB4 isoform in estrogen receptor-regulated growth of breast cancer cells. Cancer Res (2005) 1.93
Hypoxia-inducible factor-1 (HIF-1) promotes its degradation by induction of HIF-alpha-prolyl-4-hydroxylases. Biochem J (2004) 1.90
Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells. Clin Cancer Res (2006) 1.85
High frequency of BRAF V600E mutations in ameloblastoma. J Pathol (2014) 1.79
ErbB4 modulates tubular cell polarity and lumen diameter during kidney development. J Am Soc Nephrol (2011) 1.61
ERBB receptor signaling promotes ependymoma cell proliferation and represents a potential novel therapeutic target for this disease. Clin Cancer Res (2002) 1.58
Role of ErbB4 in breast cancer. J Mammary Gland Biol Neoplasia (2008) 1.57
Proteolytic cleavage and phosphorylation of a tumor-associated ErbB4 isoform promote ligand-independent survival and cancer cell growth. Mol Biol Cell (2005) 1.53
Isoform-specific monoubiquitination, endocytosis, and degradation of alternatively spliced ErbB4 isoforms. Proc Natl Acad Sci U S A (2008) 1.39
Angiopoietin-regulated recruitment of vascular smooth muscle cells by endothelial-derived heparin binding EGF-like growth factor. FASEB J (2003) 1.38
Association of Wwox with ErbB4 in breast cancer. Cancer Res (2007) 1.37
ErbB4 splice variants Cyt1 and Cyt2 differ by 16 amino acids and exert opposing effects on the mammary epithelium in vivo. Mol Cell Biol (2009) 1.28
Function of ERBB4 is determined by alternative splicing. Cell Cycle (2011) 1.26
MicroRNA profiling differentiates colorectal cancer according to KRAS status. Genes Chromosomes Cancer (2011) 1.24
The intracellular domain of ErbB4 induces differentiation of mammary epithelial cells. Mol Biol Cell (2006) 1.23
Identification of patients with transitional cell carcinoma of the bladder overexpressing ErbB2, ErbB3, or specific ErbB4 isoforms: real-time reverse transcription-PCR analysis in estimation of ErbB receptor status from cancer patients. Clin Cancer Res (2003) 1.23
Inhibition by the soluble syndecan-1 ectodomains delays wound repair in mice overexpressing syndecan-1. J Biol Chem (2004) 1.20
Type and location of tumor-infiltrating macrophages and lymphatic vessels predict survival of colorectal cancer patients. Int J Cancer (2011) 1.18
Somatic mutations of ErbB4: selective loss-of-function phenotype affecting signal transduction pathways in cancer. J Biol Chem (2008) 1.11
Endothelial cell-matrix interactions. Microsc Res Tech (2003) 1.09
Pim-1 kinase expression predicts radiation response in squamocellular carcinoma of head and neck and is under the control of epidermal growth factor receptor. Neoplasia (2009) 1.09
Cell death or survival promoted by alternative isoforms of ErbB4. Mol Biol Cell (2010) 1.07
The role of HIF prolyl hydroxylases in tumour growth. J Cell Mol Med (2010) 1.06
Overexpression and nuclear translocation of hypoxia-inducible factor prolyl hydroxylase PHD2 in head and neck squamous cell carcinoma is associated with tumor aggressiveness. Clin Cancer Res (2006) 1.05
Prolyl hydroxylase PHD3 activates oxygen-dependent protein aggregation. Mol Biol Cell (2008) 1.04
Hypoxia-activated Smad3-specific dephosphorylation by PP2A. J Biol Chem (2009) 1.00
Concurrent cetuximab, cisplatin, and radiation for squamous cell carcinoma of the head and neck in vitro. Radiother Oncol (2009) 0.98
DNA topoisomerase I is a cofactor for c-Jun in the regulation of epidermal growth factor receptor expression and cancer cell proliferation. Mol Cell Biol (2005) 0.95
Prolyl hydroxylase PHD3 enhances the hypoxic survival and G1 to S transition of carcinoma cells. PLoS One (2011) 0.94
MicroRNA profiling predicts survival in anti-EGFR treated chemorefractory metastatic colorectal cancer patients with wild-type KRAS and BRAF. Cancer Genet (2012) 0.94
Potential of ErbB4 antibodies for cancer therapy. Future Oncol (2010) 0.93
Intra- and extracellular signaling by endothelial neuregulin-1. Exp Cell Res (2007) 0.92
Hypoxic conversion of SMAD7 function from an inhibitor into a promoter of cell invasion. Cancer Res (2010) 0.91
ERBB4 mutations that disrupt the neuregulin-ErbB4 pathway cause amyotrophic lateral sclerosis type 19. Am J Hum Genet (2013) 0.90
Proteolytic processing of ErbB4 in breast cancer. PLoS One (2012) 0.90
Interaction with ErbB4 promotes hypoxia-inducible factor-1α signaling. J Biol Chem (2012) 0.89
The EGFR inhibitor gefitinib suppresses recruitment of pericytes and bone marrow-derived perivascular cells into tumor vessels. Microvasc Res (2009) 0.89
mRNA differential display of gene expression in colonic carcinoma. Electrophoresis (2002) 0.88
ErbB4 is downregulated in renal cell carcinoma--a quantitative RT-PCR and immunohistochemical analysis of the epidermal growth factor receptor family. Acta Oncol (2004) 0.88
Protein inhibitor of activated STAT3 (PIAS3) protein promotes SUMOylation and nuclear sequestration of the intracellular domain of ErbB4 protein. J Biol Chem (2012) 0.87
CYT-1 isoform of ErbB4 is an independent prognostic factor in serous ovarian cancer and selectively promotes ovarian cancer cell growth in vitro. Gynecol Oncol (2013) 0.86
The regulation, localization, and functions of oxygen-sensing prolyl hydroxylase PHD3. Biol Chem (2013) 0.85
p62/SQSTM1 regulates cellular oxygen sensing by attenuating PHD3 activity through aggregate sequestration and enhanced degradation. J Cell Sci (2013) 0.83
Biochemical and clinical approaches in evaluating the prognosis of colon cancer. Anticancer Res (2007) 0.82
Preoperative radiotherapy modulates ezrin expression and its value as a predictive marker in patients with rectal cancer. Hum Pathol (2010) 0.81
Mutated ERBB4: a novel drug target in metastatic melanoma? Pigment Cell Melanoma Res (2009) 0.81
EGFR targeting drugs in the treatment of head and neck squamous cell carcinoma. Expert Opin Emerg Drugs (2010) 0.80
ErbB targeted drugs and angiogenesis. Curr Vasc Pharmacol (2010) 0.79
Proteome analysis of cultivated vascular smooth muscle cells from a CADASIL patient. Mol Med (2007) 0.79
O-sulfated bacterial polysaccharides with low anticoagulant activity inhibit metastasis. Semin Thromb Hemost (2007) 0.78
Removal of cell surface heparan sulfate increases TACE activity and cleavage of ErbB4 receptor. BMC Cell Biol (2009) 0.77
ErbB4, a receptor tyrosine kinase, coordinates organization of the seminiferous tubules in the developing testis. Mol Endocrinol (2014) 0.76
The expression and distribution of group IIA phospholipase A2 in human colorectal tumours. Virchows Arch (2010) 0.76
ErbB4 and its isoforms: patentable drug targets? Recent Pat DNA Gene Seq (2008) 0.76
Mutations/polymorphisms in the 55 kDa subunit of DNA polymerase epsilon in human colorectal cancer. Cancer Genomics Proteomics (2010) 0.76
Systemic analysis of gene expression profiles identifies ErbB3 as a potential drug target in pediatric alveolar rhabdomyosarcoma. PLoS One (2012) 0.75
Main effects and interactions of carbonic anhydrase IX, hypoxia-inducible factor-1α, ezrin and glucose transporter-1 in multivariate analysis for disease outcome in rectal cancer. Anticancer Res (2012) 0.75
Translation of a research-based genetic test on a rare syndrome into clinical service testing, with sotos syndrome as an example. Genet Test Mol Biomarkers (2012) 0.75
Concomitant chemoirradiation with vinorelbine and gefitinib induces additive effect in head and neck squamous cell carcinoma cell lines in vitro. Radiother Oncol (2007) 0.75